GLP-1 receptor agonist medications (examples include semaglutide marketed as Ozempic and Wegovy, tirzepatide marketed as Mounjaro, and other agents such as Zepbound) mimic the gut hormone glucagon-like peptide-1 (GLP-1) and act by slowing digestion, reducing appetite, and helping to control blood sugar after meals.
January 01, 2025
high
descriptive
Mechanism of action and metabolic effects of GLP-1 receptor agonist medications used for weight loss and glycemic control.
GLP-1 medications commonly referenced for diabetes and weight loss include semaglutide and tirzepatide.
high
clinical
GLP-1 is a drug class used to treat diabetes and for weight-loss therapies.
The U.S. Food and Drug Administration states that gray-market GLP-1 drugs obtained outside the legal drug supply chain are not evaluated for safety, quality, or efficacy and may be counterfeit, contaminated, or improperly compounded.
high
regulatory
Regulatory agencies advise that products outside approved distribution and manufacturing controls carry increased safety risks.
Wegovy and Ozempic are weight-loss drugs marketed by Novo Nordisk that belong to the GLP-1 class of medications.
high
definition
Identifies the therapeutic use, manufacturer, and pharmacological class of the drugs mentioned in the article.
Eloralintide is a selective amylin receptor agonist that mimics the pancreatic hormone amylin and is intended to slow gastric emptying, reduce appetite, and help control postprandial blood glucose; this mechanism differs from GLP-1 receptor agonists, which mimic the gut hormone GLP-1.
high
descriptive
Pharmacological mechanism of action for eloralintide compared with GLP-1 receptor agonists